Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Anna Kanerva
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Living Beings
Procedures
Physiology
Chemicals & Drugs
Disorders
Anatomy
Devices
Sign-in to see full Profile
Network (preview)
44
Hemminki, Akseli
21
Hakkarainen, Tanja
19
Curiel, David
17
Bauerschmitz, Gerd
17
Desmond, Renee
11
Raki, Mari
11
Särkioja, Merja
10
Ranki, Tuuli
9
Kangasniemi, Lotta
9
Alvarez, Ronald
8
Guse, Kilian
8
Lam, John
8
Wang, Minghui
7
Ristimäki, Ari
7
Siegal, Gene
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Anna Kanerva (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Rajecki Maria; af Hällström Taija; Hakkarainen Tanja; Nokisalmi Petri; Hautaniemi Sampsa; Nieminen Anni I; Tenhunen Mikko; Rantanen Ville; Desmond Reneé A; Chen Dung-Tsa; Guse Kilian; Stenman Ulf-Håkan; Gargini Ricardo; Kapanen Mika; Klefström Juha; Kanerva Anna; Pesonen Sari; Ahtiainen Laura; Hemminki Akseli
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
International journal of cancer. Journal international du cancer 2009;125(10):2441-9.
-
2009: Koski Anniina; Rajecki Maria; Guse Kilian; Kanerva Anna; Ristimäki Ari; Pesonen Sari; Escutenaire Sophie; Hemminki Akseli
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.
The journal of gene medicine 2009;11(11):966-77.
-
2009: Guse K; Diaconu I; Rajecki M; Sloniecka M; Hakkarainen T; Ristimäki A; Kanerva A; Pesonen S; Hemminki A
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.
Gene therapy 2009;16(8):1009-20.
-
2009: Diaconu Iulia; Denby Laura; Pesonen Sari; Cerullo Vincenzo; Bauerschmitz Gerd J; Guse Kilian; Rajecki Maria; Dias João D; Taari Kimmo; Kanerva Anna; Baker Andrew H; Hemminki Akseli
Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver.
Human gene therapy 2009;20(6):611-20.
-
2009: Kangasniemi L; Koskinen M; Jokinen M; Toriseva M; Ala-Aho R; Kähäri V-M; Jalonen H; Ylä-Herttuala S; Moilanen H; Stenman U-H; Diaconu I; Kanerva A; Pesonen S; Hakkarainen T; Hemminki A
Extended release of adenovirus from silica implants in vitro and in vivo.
Gene therapy 2009;16(1):103-10.
-
2008: Bauerschmitz Gerd J; Ranki Tuuli; Kangasniemi Lotta; Ribacka Camilla; Eriksson Minna; Porten Marius; Herrmann Isabell; Ristimäki Ari; Virkkunen Pekka; Tarkkanen Maija; Hakkarainen Tanja; Kanerva Anna; Rein Daniel; Pesonen Sari; Hemminki Akseli
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
Cancer research 2008;68(14):5533-9.
-
2008: Särkioja Merja; Hakkarainen Tanja; Eriksson Minna; Ristimäki Ari; Desmond Renee A; Kanerva Anna; Hemminki Akseli
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.
The journal of gene medicine 2008;10(7):744-53.
-
2008: Särkioja M; Pesonen S; Raki M; Hakkarainen T; Salo J; Ahonen M T; Kanerva A; Hemminki A
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
Gene therapy 2008;15(12):921-9.
-
2008: Raki Mari; Särkioja Merja; Desmond Renee A; Chen Dung-Tsa; Bützow Ralf; Hemminki Akseli; Kanerva Anna
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Gynecologic oncology 2008;108(1):166-72.
-
2008: Kanerva Anna; Lavilla-Alonso Sergio; Raki Mari; Kangasniemi Lotta; Bauerschmitz Gerd J; Takayama Koichi; Ristimäki Ari; Desmond Renee A; Hemminki Akseli
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses.
PloS one 2008;3(8):e2917.
-
2007: Eriksson Minna; Guse Kilian; Bauerschmitz Gerd; Virkkunen Pekka; Tarkkanen Maija; Tanner Minna; Hakkarainen Tanja; Kanerva Anna; Desmond Renee A; Pesonen Sari; Hemminki Akseli
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(12):2088-93.
-
2007: Guse Kilian; Ranki Tuuli; Ala-Opas Martti; Bono Petri; Särkioja Merja; Rajecki Maria; Kanerva Anna; Hakkarainen Tanja; Hemminki Akseli
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
Molecular cancer therapeutics 2007;6(10):2728-36.
-
2007: Raki M; Hakkarainen T; Bauerschmitz G J; Särkioja M; Desmond R A; Kanerva A; Hemminki A
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Gene therapy 2007;14(19):1380-8.
-
2007: Kanerva Anna; Raki Mari; Hemminki Akseli
Gene therapy of gynaecological diseases.
Expert opinion on biological therapy 2007;7(9):1347-61.
-
2007: Hakkarainen Tanja; Särkioja Merja; Lehenkari Petri; Miettinen Susanna; Ylikomi Timo; Suuronen Riitta; Desmond Renee A; Kanerva Anna; Hemminki Akseli
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
Human gene therapy 2007;18(7):627-41.
-
2007: Ranki Tuuli; Särkioja Merja; Hakkarainen Tanja; von Smitten Karl; Kanerva Anna; Hemminki Akseli
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
International journal of cancer. Journal international du cancer 2007;121(1):165-74.
-
2007: Guse K; Dias J D; Bauerschmitz G J; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond R A; Kanerva A; Hemminki A
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Gene therapy 2007;14(11):902-11.
-
2007: Lam J T; Hemminki A; Kanerva A; Lee K B; Blackwell J L; Desmond R; Siegal G P; Curiel D T
A three-dimensional assay for measurement of viral-induced oncolysis.
Cancer gene therapy 2007;14(4):421-30.
-
2007: Rajecki Maria; Kanerva Anna; Stenman Ulf-Håkan; Tenhunen Mikko; Kangasniemi Lotta; Särkioja Merja; Ala-Opas Martti Y; Alfthan Henrik; Sankila Anna; Rintala Erkki; Desmond Renee A; Hakkarainen Tanja; Hemminki Akseli
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.
Molecular cancer therapeutics 2007;6(2):742-51.
-
2007: Kanerva Anna; Raki Mari; Ranki Tuuli; Särkioja Merja; Koponen Jarmo; Desmond Renee A; Helin Aija; Stenman Ulf-Håkan; Isoniemi Helena; Höckerstedt Krister; Ristimäki Ari; Hemminki Akseli
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity.
The journal of gene medicine 2007;9(1):3-9.
-
2007: Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Gene therapy 2007;14(1):58-67.
-
2006: Sarkioja Merja; Kanerva Anna; Salo Jarmo; Kangasniemi Lotta; Eriksson Minna; Raki Mari; Ranki Tuuli; Hakkarainen Tanja; Hemminki Akseli
Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.
Cancer 2006;107(7):1578-88.
-
2006: Raki Mari; Rein Daniel T; Kanerva Anna; Hemminki Akseli
Gene transfer approaches for gynecological diseases.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(2):154-63.
-
2006: Bauerschmitz Gerd J; Guse Kilian; Kanerva Anna; Menzel Artur; Herrmann Isabell; Desmond Renee A; Yamamoto Masato; Nettelbeck Dirk M; Hakkarainen Tanja; Dall Peter; Curiel David T; Hemminki Akseli
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(2):164-74.
-
2006: Kangasniemi Lotta; Kiviluoto Tuula; Kanerva Anna; Raki Mari; Ranki Tuuli; Sarkioja Merja; Wu Hongju; Marini Frank; Höckerstedt Krister; Isoniemi Helena; Alfthan Henrik; Stenman Ulf-Håkan; Curiel David T; Hemminki Akseli
Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):3137-44.
-
2005: Raki M; Kanerva A; Ristimaki A; Desmond R A; Chen D-T; Ranki T; Sarkioja M; Kangasniemi L; Hemminki A
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Gene therapy 2005;12(15):1198-205.
-
2005: Kanerva A; Zinn K R; Peng K-W; Ranki T; Kangasniemi L; Chaudhuri T R; Desmond R A; Wang M; Takayama K; Hakkarainen T; Alfthan H; Stenman U-H; Curiel D T; Hemminki A
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus.
Gene therapy 2005;12(1):87-94.
-
2005: Hakkarainen Tanja; Kanerva Anna; Hemminki Akseli
[Adenoviruses in cancer therapy]
Duodecim; lääketieteellinen aikakauskirja 2005;121(20):2195-203.
-
2005: Kanerva Anna; Hemminki Akseli
Adenoviruses for treatment of cancer.
Annals of medicine 2005;37(1):33-43.
-
2004: Lam John T; Kanerva Anna; Bauerschmitz Gerd J; Takayama Koichi; Suzuki Kaori; Yamamoto Masato; Bhoola Snehal M; Liu Bin; Wang Minghui; Barnes Mack N; Alvarez Ronald D; Siegal Gene P; Curiel David T; Hemminki Akseli
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
The journal of gene medicine 2004;6(12):1333-42.
-
2004: Bauerschmitz Gerd J; Kanerva Anna; Wang Minghui; Herrmann Isabell; Shaw Denise R; Strong Theresa V; Desmond Renee; Rein Daniel T; Dall Peter; Curiel David T; Hemminki Akseli
Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer.
International journal of cancer. Journal international du cancer 2004;111(2):303-9.
-
2004: Kanerva Anna; Hemminki Akseli
Modified adenoviruses for cancer gene therapy.
International journal of cancer. Journal international du cancer 2004;110(4):475-80.
-
2004: Kanerva A; Bauerschmitz G J; Yamamoto M; Lam J T; Alvarez R D; Siegal G P; Curiel D T; Hemminki A
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
Gene therapy 2004;11(6):552-9.
-
2003: Volk Andrea L; Rivera Angel A; Kanerva Anna; Bauerschmitz Gerd; Dmitriev Igor; Nettelbeck Dirk M; Curiel David T
Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism.
Cancer biology & therapy 2003;2(5):511-5.
-
2003: Kanerva Anna; Zinn Kurt R; Chaudhuri Tandra R; Lam John T; Suzuki Kaori; Uil Taco G; Hakkarainen Tanja; Bauerschmitz Gerd J; Wang Minghui; Liu Bin; Cao Zhihong; Alvarez Ronald D; Curiel David T; Hemminki Akseli
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;8(3):449-58.
-
2003: Lam John T; Bauerschmitz Gerd J; Kanerva Anna; Barker Shannon D; Straughn J Michael; Wang Minghui; Barnes Mack N; Blackwell Jerry L; Siegal Gene P; Alvarez Ronald D; Curiel David T; Hemminki Akseli
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids.
Cancer gene therapy 2003;10(5):377-87.
-
2003: Barker Shannon D; Coolidge Candace J; Kanerva Anna; Hakkarainen Tanja; Yamamoto Masato; Liu Bin; Rivera Angel A; Bhoola Snehal M; Barnes Mack N; Alvarez Ronald D; Curiel David T; Hemminki Akseli
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
The journal of gene medicine 2003;5(4):300-10.
-
2003: Hemminki Akseli; Kanerva Anna; Kremer Eric J; Bauerschmitz Gerd J; Smith Bruce F; Liu Bin; Wang Minghui; Desmond Renee A; Keriel Anne; Barnett Brian; Baker Henry J; Siegal Gene P; Curiel David T
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(2):163-73.
-
2003: Hemminki Akseli; Kanerva Anna; Liu Bin; Wang Minghui; Alvarez Ronald D; Siegal Gene P; Curiel David T
Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.
Cancer research 2003;63(4):847-53.
-
2003: Hakkarainen Tanja; Hemminki Akseli; Pereboev Alexander V; Barker Shannon D; Asiedu Clement K; Strong Theresa V; Kanerva Anna; Wahlfors Jarmo; Curiel David T
CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):619-24.
-
2002: Haviv Yosef S; Blackwell Jerry L; Kanerva Anna; Nagi Peter; Krasnykh Victor; Dmitriev Igor; Wang Minghui; Naito Seiji; Lei Xiaosheng; Hemminki Akseli; Carey Delicia; Curiel David T
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.
Cancer research 2002;62(15):4273-81.
-
2002: Kanerva Anna; Wang Minghui; Bauerschmitz Gerd J; Lam John T; Desmond Renee A; Bhoola Snehal M; Barnes Mack N; Alvarez Ronald D; Siegal Gene P; Curiel David T; Hemminki Akseli
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.
Molecular therapy : the journal of the American Society of Gene Therapy 2002;5(6):695-704.
-
2002: Bauerschmitz Gerd J; Nettelbeck Dirk M; Kanerva Anna; Baker Andrew H; Hemminki Akseli; Reynolds Paul N; Curiel David T
The flt-1 promoter for transcriptional targeting of teratocarcinoma.
Cancer research 2002;62(5):1271-4.
-
2002: Bauerschmitz Gerd J; Lam John T; Kanerva Anna; Suzuki Kaori; Nettelbeck Dirk M; Dmitriev Igor; Krasnykh Victor; Mikheeva Galina V; Barnes Mack N; Alvarez Ronald D; Dall Peter; Alemany Ramon; Curiel David T; Hemminki Akseli
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.
Cancer research 2002;62(5):1266-70.
-
2002: Kanerva Anna; Mikheeva Galina V; Krasnykh Victor; Coolidge Candace J; Lam John T; Mahasreshti Parameshwar J; Barker Shannon D; Straughn Michael; Barnes Mack N; Alvarez Ronald D; Hemminki Akseli; Curiel David T
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):275-80.
Sign-in to see more
